NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free DRRX Stock Alerts $1.21 -0.13 (-9.70%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.17▼$1.3050-Day Range$0.71▼$1.3752-Week Range$0.47▼$7.46Volume234,251 shsAverage Volume185,749 shsMarket Capitalization$36.09 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get DURECT alerts: Email Address DURECT MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,792.6% Upside$35.00 Price TargetShort InterestHealthy3.72% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews Sentiment0.27Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.46) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.80 out of 5 starsMedical Sector262nd out of 938 stocksPharmaceutical Preparations Industry121st out of 438 stocks 3.3 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, DURECT has a forecasted upside of 2,792.6% from its current price of $1.21.Amount of Analyst CoverageDURECT has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.72% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in DURECT has recently decreased by 1.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 2.4 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for DURECT this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows4 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($1.46) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About DURECT Stock (NASDAQ:DRRX)DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comDURECT (NASDAQ:DRRX) Raised to "Hold" at StockNews.comMarch 27, 2024 | benzinga.comDurect: Q4 Earnings InsightsMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 27, 2024 | markets.businessinsider.comDURECT Corp. Q4 Loss decreases, beats estimatesMarch 27, 2024 | finance.yahoo.comDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 27, 2024March 27, 2024 | msn.comDURECT Q4 2023 Earnings PreviewMarch 25, 2024 | americanbankingnews.comDURECT (DRRX) to Release Earnings on WednesdayMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 23, 2024 | americanbankingnews.comDURECT (NASDAQ:DRRX) & Biora Therapeutics (NASDAQ:BIOR) Financial SurveyMarch 20, 2024 | finance.yahoo.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 20, 2024 | prnewswire.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 20, 2024 | americanbankingnews.comDURECT Co. (NASDAQ:DRRX) Short Interest Up 6.6% in FebruaryMarch 19, 2024 | americanbankingnews.comDURECT (NASDAQ:DRRX) Downgraded by StockNews.com to "Sell"March 16, 2024 | finance.yahoo.comDRRX Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comDRRX Apr 2024 0.500 putMarch 4, 2024 | markets.businessinsider.comDURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product LineMarch 4, 2024 | msn.comDURECT and Charles River enter agreement for alzet in U.S., CanadaMarch 4, 2024 | finance.yahoo.comDURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and CanadaFebruary 24, 2024 | finance.yahoo.comDRRX Mar 2024 1.500 putFebruary 7, 2024 | finance.yahoo.comDURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 29, 2024 | msn.comEarth Science Tech to effect up to $5M stock repurchase programNovember 16, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Taysha Gene Therapies (TSHA) and Durect (DRRX)November 15, 2023 | seekingalpha.comDURECT: Reading Into AHFIRM Mortality RatesNovember 13, 2023 | benzinga.comRecap: Durect Q3 EarningsNovember 13, 2023 | finance.yahoo.comDURECT Corporation Reports Third Quarter 2023 Financial Results and Business UpdateNovember 12, 2023 | morningstar.comDurect Corp DRRXSee More Headlines Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2021Today3/29/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees72Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$41.00 Low Stock Price Target$27.00 Potential Upside/Downside+2,792.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-398.65% Pretax Margin-398.65% Return on Equity-289.99% Return on Assets-78.74% Debt Debt-to-Equity RatioN/A Current Ratio1.19 Quick Ratio1.12 Sales & Book Value Annual Sales$19.28 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book1.10Miscellaneous Outstanding Shares29,830,000Free Float28,546,000Market Cap$36.09 million OptionableOptionable Beta0.82 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. James E. Brown D.V.M. (Age 67)Co-Founder, CEO, President & Director Comp: $885.86kMs. Judy R. Joice (Age 67)Senior Vice President of Operations & Corporate Quality Assurance Comp: $451.82kDr. Norman L. Sussman M.D. (Age 71)Chief Medical Officer Comp: $587.95kMr. Timothy M. Papp M.B.A. (Age 48)CFO & Secretary Ms. Jian Li M.B.A. (Age 54)Interim Principal Accounting Officer, Senior VP of Finance, Corporate Controller & Secretary Comp: $297.08kDr. WeiQi Lin M.D.Ph.D., Executive VP of Research & Development and Principal ScientistMr. Keith L. Lui M.B.A.Senior Vice President of Business Development, Commercial & Medical AffairsDr. Su Il Yum Ph.D. (Age 85)Executive Officer Comp: $331.74kMore ExecutivesKey CompetitorsMarker TherapeuticsNASDAQ:MRKRProMIS NeurosciencesNASDAQ:PMNBiora TherapeuticsNASDAQ:BIORVYNE TherapeuticsNASDAQ:VYNECara TherapeuticsNASDAQ:CARAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 26,421 shares on 3/11/2024Ownership: 3.595%Virtu Financial LLCBought 44,292 shares on 2/26/2024Ownership: 0.148%Vanguard Group Inc.Bought 26,421 shares on 2/15/2024Ownership: 3.595%Barclays PLCBought 32,200 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCSold 1,900 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions DRRX Stock Analysis - Frequently Asked Questions Should I buy or sell DURECT stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks. What is DURECT's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month target prices for DURECT's stock. Their DRRX share price targets range from $27.00 to $41.00. On average, they anticipate the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 2,792.6% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2024? DURECT's stock was trading at $0.59 at the start of the year. Since then, DRRX shares have increased by 105.1% and is now trading at $1.21. View the best growth stocks for 2024 here. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative net margin of 398.65% and a negative trailing twelve-month return on equity of 289.99%. During the same period in the prior year, the firm posted ($0.50) earnings per share. When did DURECT's stock split? DURECT's stock reverse split on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). Who are DURECT's major shareholders? DURECT's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.60%), Vanguard Group Inc. (3.60%), Richmond Brothers Inc. (1.74%), Silverberg Bernstein Capital Management LLC (0.16%), Virtu Financial LLC (0.15%) and Barclays PLC (0.00%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.